NCT04774952 2025-04-15Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Completed58 enrolled
NCT05462717 2024-11-07Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1 Active not recruiting222 enrolled
NCT03634982 2022-09-01Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Unknown133 enrolled
NCT02897778 2022-04-28Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid TumorsSyndax PharmaceuticalsPhase 1 Completed30 enrolled
NCT02909452 2022-01-25Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid TumorsSyndax PharmaceuticalsPhase 1 Completed30 enrolled